Over the last three years Synpromics’ revenue has increased by over 2400%, with an accumulated deal value of over £300 million. This growth has been accompanied by a move to expanded facilities to accommodate additional staff and the opening of business development activities in the US.
The Deloitte Fast 50 recognises this sustained growth and the ongoing development of Synpromics’ proprietary synthetic promoter technology.
“We are thrilled to rank as one of the fastest growing technology companies in the UK. This recognises the team’s hard work in developing our technology and forming important and valuable partnerships across industry and academia. We look forward to continuing to grow, developing our technology to facilitate the production of gene therapies for a range of diseases.”
Michael Roberts, CSO of Synpromics
This accolade follows the recent announcement of positive pre-clinical data from uniQure, a key partner, using a liver-selective promoter developed by Synpromics. The data demonstrates that the promoter is at least eight times more potent than the current industry standard.
Photo courtesy of Deloitte: Alexander Crawford (Calculus Capital Investment Director) and Michael Roberts (Synpromics CSO and Founder)
For further information, contact:
David Venables, Chief Executive Officer
T: +44 (0)131 651 9662
Deborah Cockerill / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801